Enveda Biosciences has filed a notice of an exempt offering of securities to raise $62,459,761.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Enveda Biosciences is raising $62,459,761.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Viswa Colluru played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Enveda Biosciences
At Enveda, we are systematically translating molecules found in medicinal plants into new drugs for challenging diseases. Our platform harnesses natures complexity with the help of cutting-edge advancements in knowledge graphs, machine learning, and metabolomics. Natures chemistry has evolved under billions of years of selective pressure to modulate lifes fundamental phenomena. This has led to incredible diversity of chemical properties and biological activity. This diversity is uncharacteristic of historical small molecule libraries and inaccessible to even cutting-edge library generation technologies. Were harnessing this ancient cache to rapidly discover and deliver new medicines, and hope, to patients suffering a range of complex diseases. Our chemistry provides a unique opportunity to access known and emerging mechanisms of tuning biological activity of proteins. We are rapidly identifying novel chemistries that provide new and useful mechanisms for manipulating disease-relevant proteins. These include chemistries that can degrade or stabilize proteins, that can change the shape of difficult-to-drug proteins thus allowing modulation of target, or that can covalently inhibit specific proteins. Uncovering how natures diverse chemistry manipulates human biology is a powerful way to understand the basis of disease. Just as the study of rapamycin once led to the discovery of mTOR signaling, we have built technologies that rapidly uncover novel disease targets while simultaneously advancing these molecules as new medicines.
To learn more about Enveda Biosciences, visit http://www.envedabio.com/
Contact:
Viswa Colluru, Chief Executive Officer
415-323-5252
https://www.linkedin.com/in/viswacolluru/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.